Dietmar Berger's most recent trade in Gilead Sciences, Inc. was a trade of 37,710 Non-qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 10, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences, Inc. | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 37,710 | 37,710 | - | - | Non-qualified Stock Option (Right to Buy) | |
Gilead Sciences, Inc. | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2025 | 8,530 | 57,505 | - | - | Restricted Stock Unit | |
Gilead Sciences, Inc. | Dietmar Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 48,975 | 48,975 | - | - | Restricted Stock Unit |